MA38561B1 - Anticorps anti-igf-1r à liaison fcrn abolie et leur utilisation dans le traitement de maladies vasculaires oculaires - Google Patents
Anticorps anti-igf-1r à liaison fcrn abolie et leur utilisation dans le traitement de maladies vasculaires oculairesInfo
- Publication number
- MA38561B1 MA38561B1 MA38561A MA38561A MA38561B1 MA 38561 B1 MA38561 B1 MA 38561B1 MA 38561 A MA38561 A MA 38561A MA 38561 A MA38561 A MA 38561A MA 38561 B1 MA38561 B1 MA 38561B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- treatment
- fcrn
- igf
- abbreviated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13165741 | 2013-04-29 | ||
| PCT/EP2014/058418 WO2014177461A1 (en) | 2013-04-29 | 2014-04-25 | Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38561A1 MA38561A1 (fr) | 2017-09-29 |
| MA38561B1 true MA38561B1 (fr) | 2018-09-28 |
Family
ID=48190315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38561A MA38561B1 (fr) | 2013-04-29 | 2014-04-25 | Anticorps anti-igf-1r à liaison fcrn abolie et leur utilisation dans le traitement de maladies vasculaires oculaires |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR096092A1 (es) |
| MA (1) | MA38561B1 (es) |
| MY (1) | MY181915A (es) |
-
2014
- 2014-04-25 MY MYPI2015703843A patent/MY181915A/en unknown
- 2014-04-25 MA MA38561A patent/MA38561B1/fr unknown
- 2014-04-25 AR ARP140101717A patent/AR096092A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY181915A (en) | 2021-01-14 |
| MA38561A1 (fr) | 2017-09-29 |
| AR096092A1 (es) | 2015-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR23C1010I2 (fr) | Anticorps bispecifiques anti-ang-2/anti-vegf et leur utilisation dans le traitement des maladies vasculaires oculaires | |
| FR24C1001I1 (fr) | Anticorps anti-pd1 et leur utilisation en tant qu'agents thérapeutiques et de diagnostic | |
| EA202091587A1 (ru) | Анти-tigit антитела и их применение в качестве терапевтических и диагностических средств | |
| MA44254A (fr) | Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques | |
| EA201690633A1 (ru) | Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела | |
| EA201890278A1 (ru) | Антитела к pd-l1 | |
| EA201790377A1 (ru) | Антитела к глюкагону и их применения | |
| EA201691266A1 (ru) | Анти-cd3 антитела и способы применения | |
| EA201491530A1 (ru) | Модуляторы рецепторов эстрогенов и их применение | |
| EA202193044A2 (ru) | Способы лечения таупатии | |
| PH12015501656A1 (en) | Anti-il-33 antibodies and use thereof | |
| EA201891732A1 (ru) | Биспецифичные связывающие белки для pd-l1 и kdr | |
| MA40510A (fr) | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t | |
| BR112016023948A2 (pt) | proteínas fc multiméricas | |
| MA43982A (fr) | Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1 | |
| UA118674C2 (uk) | Антитіло до igf-1r з елімінованою здатністю зв'язуватися з fcrn та його застосування для лікування судинних захворювань очей | |
| EA202090031A3 (ru) | Человеческие антитела против gfr3 и способы их применения | |
| MA35660B1 (fr) | Inhibiteurs de la protéine pak pour le traitement du syndrome de l'x fragile | |
| BR112016020377A2 (pt) | proteínas fc multiméricas | |
| MA43113A (fr) | Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci | |
| MA47205A (fr) | Anticorps spécifiques de la protéine tau hyperphosphorylée pour traiter des maladies oculaires | |
| EA201492282A1 (ru) | Антагонистические антигенсвязывающие белки к двум рецепторам и их применение | |
| MA39342B2 (fr) | Anticorps il -21 | |
| EA201692402A1 (ru) | Лекарственные формы для местного применения и их использование | |
| MA38485A1 (fr) | Anticorps anti-cd52 humains pour une utilisation dans le traitement, par exemple, des maladies auto-immunes, le cancer, et le rejet de greffe |